Key facts
- Pharus Diagnostics’s last known valuation is $43.0M (Apr 2025).
- It has raised $17.1M; the latest was Early Stage VC ($6.1M) in Apr 2025.
- Notable investors include Lee Family Office, CK Hutchison, CK Life Sciences International, Larta Institute, QuarkBio.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pharus Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pharus Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pharus Diagnostics
Developer and provider of liquid biopsy tests intended for the early detection of cancer. The company's tests leverage its enhanced RNA-based genetic testing solution and integrates additional diverse omics data to achieve cancer detection in a single analysis, enabling users to manage their health outcomes better and earlier.
- Sector
- Healthcare
- HQ
- Zhubei City, Taiwan
- Founded
- 2022
- Employees
- 21
- Website
- pharusdx.com/
- Ownership
- Privately Held (backing)
Pharus Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pharus Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pharus Diagnostics in its N-PORT filings yet. We sweep new filings monthly.